{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:50:33Z","timestamp":1791931833101,"version":"4.3.4"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2R01AI139261"],"award-info":[{"award-number":["2R01AI139261"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 A1141349"],"award-info":[{"award-number":["T32 A1141349"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American College of Clinical Pharmacy Foundation Junior Investigator Research Award","award":["G0507743"],"award-info":[{"award-number":["G0507743"]}]},{"name":"Society of Infectious Diseases Pharmacists Early Career Research Award","award":["G0507861"],"award-info":[{"award-number":["G0507861"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Epidemiologic studies have shown decreasing vancomycin susceptibility among clinical Clostridioides difficile isolates, but the impact on patient outcomes is unknown. We hypothesized that reduced vancomycin susceptibility would be associated with decreased rates of sustained clinical response (SCR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This multicenter cohort study included adults with C. difficile infection (CDI) treated with oral vancomycin between 2016 and 2021. Clostridioides difficile isolates underwent agar dilution vancomycin susceptibility testing, ribotyping, and Sanger sequencing of the vancomycin resistance vanR gene. Reduced susceptibility was defined as vancomycin minimum inhibitory concentration (MIC) &amp;gt;2\u2005\u03bcg\/mL. The primary outcome was 30-day SCR; secondary outcomes were 14-day initial cure, 30-day recurrence, and 30-day mortality. Exploratory analysis assessed the association between the VanR Thr115Ala polymorphism, susceptibility, and outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A high proportion (34% [102\/300]) of C. difficile isolates exhibited reduced vancomycin susceptibility (range, 0.5\u201316\u2005\u03bcg\/mL; MIC50\/90 = 2\/4\u2005\u03bcg\/mL). Ribotype 027 accounted for the highest proportion (77.4% [41\/53]) of isolates with reduced vancomycin susceptibility. Overall, 83% (249) of patients achieved 30-day SCR. Reduced vancomycin susceptibility was associated with lower rates of 30-day SCR (76% [78\/102]) than vancomycin-susceptible strains (86% [171\/198]; P = .031). A significantly lower rate of 14-day initial cure was also observed among individuals infected with strains with reduced vancomycin susceptibility (89% vs 96%; P = .04). Reduced susceptibility remained an independent predictor of 30-day SCR in multivariable modeling (odds ratio, 0.52 [95% confidence interval, .28\u2013.97]; P = .04).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Reduced vancomycin susceptibility in C. difficile was associated with decreased odds of 30-day SCR and lower 14-day initial cure rates in the studied patient cohort.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae087","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T22:04:17Z","timestamp":1708380257000},"page":"15-21","source":"Crossref","is-referenced-by-count":39,"title":["Reduced Vancomycin Susceptibility in <i>Clostridioides difficile<\/i> Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6645-406X","authenticated-orcid":false,"given":"Taryn A","family":"Eubank","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetna","family":"Dureja","sequence":"additional","affiliation":[{"name":"Center of Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M Health Science Center , Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W","family":"Garey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian G","family":"Hurdle","sequence":"additional","affiliation":[{"name":"Center of Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M Health Science Center , Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-359X","authenticated-orcid":false,"given":"Anne J","family":"Gonzales-Luna","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"2024071918112942400_ciae087-B1","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","article-title":"Changes in prevalence of health care-associated infections in U.S. hospitals","volume":"379","author":"Magill","year":"2018","journal-title":"N Engl J Med"},{"key":"2024071918112942400_ciae087-B2","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"2024071918112942400_ciae087-B3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in U.S. burden of Clostridioides difficile infection and outcomes","volume":"382","author":"Guh","year":"2020","journal-title":"N Engl J Med"},{"key":"2024071918112942400_ciae087-B4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/cid\/cis386","article-title":"The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999\u20132007","volume":"55","author":"Hall","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024071918112942400_ciae087-B5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/ciab718","article-title":"Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024071918112942400_ciae087-B6","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2024071918112942400_ciae087-B7","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/cid\/ciaa484","article-title":"Impact of revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America clinical practice guidelines on the treatment of Clostridium difficile infections in the United States","volume":"72","author":"Clancy","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024071918112942400_ciae087-B8","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1017\/S0950268817000644","article-title":"Compliance with Clostridium difficile treatment guidelines: effect on patient outcomes","volume":"145","author":"Crowell","year":"2017","journal-title":"Epidemiol Infect"},{"key":"2024071918112942400_ciae087-B9","doi-asserted-by":"crossref","first-page":"2050312120986733","DOI":"10.1177\/2050312120986733","article-title":"Clinical complications in patients with primary and recurrent Clostridioides difficile infection: a real-world data analysis","volume":"9","author":"Feuerstadt","year":"2021","journal-title":"SAGE Open Med"},{"key":"2024071918112942400_ciae087-B10","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"2024071918112942400_ciae087-B11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile\u2013associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024071918112942400_ciae087-B12","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1128\/AAC.00504-15","article-title":"Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection","volume":"59","author":"Louie","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024071918112942400_ciae087-B13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1473-3099(17)30235-9","article-title":"Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study","volume":"17","author":"Vickers","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2024071918112942400_ciae087-B14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/cid\/cis430","article-title":"Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain","volume":"55","author":"Petrella","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024071918112942400_ciae087-B15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/cid\/ciaa912","article-title":"Emergence of clinical Clostridioides difficile isolates with decreased susceptibility to vancomycin","volume":"74","author":"Darkoh","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024071918112942400_ciae087-B16","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1128\/AAC.00845-15","article-title":"U.S.-based national sentinel surveillance study for the epidemiology of Clostridium difficile\u2013associated diarrheal isolates and their susceptibility to fidaxomicin","volume":"59","author":"Snydman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024071918112942400_ciae087-B17","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/jac\/dky135","article-title":"Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin","volume":"73","author":"Snydman","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024071918112942400_ciae087-B18","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1128\/AAC.02775-13","article-title":"Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013","volume":"58","author":"Tickler","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024071918112942400_ciae087-B19","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/jac\/dkab099","article-title":"Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015\u201318","volume":"76","author":"Putsathit","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024071918112942400_ciae087-B20","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1038\/s41598-020-61604-z","article-title":"High prevalence of Clostridioides difficile PCR ribotypes 001 and 126 in Iran","volume":"10","author":"Baghani","year":"2020","journal-title":"Sci Rep"},{"key":"2024071918112942400_ciae087-B21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.diagmicrobio.2015.05.015","article-title":"A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole","volume":"83","author":"Adler","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024071918112942400_ciae087-B22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkz513","article-title":"Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates","volume":"75","author":"Shen","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024071918112942400_ciae087-B23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/antibiotics11020258","article-title":"Genetic mechanisms of vancomycin resistance in Clostridioides difficile: a systematic review","volume":"11","author":"Eubank","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2024071918112942400_ciae087-B24","first-page":"1677","article-title":"Reference susceptibility testing and genomic surveillance of Clostridioides difficile, United States, 2012\u201317","volume":"75","author":"Gargis","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024071918112942400_ciae087-B25","doi-asserted-by":"crossref","first-page":"e0377722","DOI":"10.1128\/spectrum.03777-22","article-title":"The vanR Cd mutation 343A &gt; G, resulting in a Thr115Ala substitution, is associated with an elevated minimum inhibitory concentration (MIC) of vancomycin in Clostridioides difficile clinical isolates from Florida","volume":"11","author":"Wickramage","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2024071918112942400_ciae087-B26","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1128\/AAC.00625-11","article-title":"Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection","volume":"55","author":"Goldstein","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024071918112942400_ciae087-B27","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2020.10.046","article-title":"Plasmid acquisition alters vancomycin susceptibility in Clostridioides difficile","volume":"160","author":"Pu","year":"2021","journal-title":"Gastroenterology"},{"key":"2024071918112942400_ciae087-B28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2334-10-363","article-title":"Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection","volume":"10","author":"Gonzales","year":"2010","journal-title":"BMC Infect Dis"},{"key":"2024071918112942400_ciae087-B29","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1093\/jac\/dkaa364","article-title":"A randomized, double-blind, placebo-controlled, single and multiple ascending dose phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects","volume":"75","author":"Garey","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024071918112942400_ciae087-B30","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3389\/fmicb.2018.01420","article-title":"Detection and investigation of eagle effect resistance to vancomycin in Clostridium difficile with an ATP-bioluminescence assay","volume":"9","author":"Jarrad","year":"2018","journal-title":"Front Microbiol"},{"key":"2024071918112942400_ciae087-B31","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jac\/dkv006","article-title":"In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile","volume":"70","author":"Corbett","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2024071918112942400_ciae087-B32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000104471","article-title":"Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile","volume":"53","author":"Odenholt","year":"2007","journal-title":"Chemotherapy"},{"key":"2024071918112942400_ciae087-B33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.mib.2022.01.004","article-title":"Mechanisms and impact of antimicrobial resistance in Clostridioides difficile","volume":"66","author":"Dureja","year":"2022","journal-title":"Curr Opin Microbiol"},{"issue":"Suppl 2","key":"2024071918112942400_ciae087-B34","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1093\/cid\/cis357","article-title":"Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin","volume":"55","author":"Figueroa","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024071918112942400_ciae087-B35","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"2024071918112942400_ciae087-B36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2024071918112942400_ciae087-B37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.anaerobe.2014.03.002","article-title":"Investigation of potentially pathogenic Clostridium difficile contamination in household environs","volume":"27","author":"Alam","year":"2014","journal-title":"Anaerobe"},{"key":"2024071918112942400_ciae087-B38","volume-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018","edition":"9th ed"},{"key":"2024071918112942400_ciae087-B39","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2024071918112942400_ciae087-B40","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2023","edition":"33rd ed"},{"key":"2024071918112942400_ciae087-B41","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024071918112942400_ciae087-B42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1365-2958.1996.00617.x","article-title":"Quantitative analysis of the metabolism of soluble cytoplasmic peptidoglycan precursors of glycopeptide-resistant enterococci","volume":"21","author":"Arthur","year":"1996","journal-title":"Mol Microbiol"},{"key":"2024071918112942400_ciae087-B43","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease","volume":"97","author":"McFarland","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 6","key":"2024071918112942400_ciae087-B44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1469-0691.12046","article-title":"Can we identify patients at high risk of recurrent Clostridium difficile infection?","volume":"18","author":"Kelly","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2024071918112942400_ciae087-B45","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jiac.2018.05.010","article-title":"Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative phase III study in Japan","volume":"24","author":"Mikamo","year":"2018","journal-title":"J Infect Chemother"},{"key":"2024071918112942400_ciae087-B46","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(17)30751-X","article-title":"Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b\/4 trial","volume":"18","author":"Guery","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024071918112942400_ciae087-B47","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/cid\/ciac444","article-title":"Houston, we have a problem: reports of Clostridioides difficile isolates with reduced vancomycin susceptibility","volume":"75","author":"Greentree","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024071918112942400_ciae087-B48","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/676433","article-title":"Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile\u2013associated disease rates","volume":"35","author":"Koo","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024071918112942400_ciae087-B49","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1093\/jac\/dkaa251","article-title":"Utilizing antibiotics to prevent Clostridioides difficile infection: does exposure to a risk factor decrease risk? A systematic review","volume":"75","author":"Carlson","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024071918112942400_ciae087-B50","doi-asserted-by":"crossref","first-page":"ofab365","DOI":"10.1093\/ofid\/ofab365","article-title":"Reduced susceptibility to metronidazole is associated with initial clinical failure in Clostridioides difficile infection","volume":"8","author":"Gonzales-Luna","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024071918112942400_ciae087-B51","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/jac\/dkad194","article-title":"In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile","volume":"78","author":"Marchandin","year":"2023","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae087\/57086722\/ciae087.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/1\/15\/58599912\/ciae087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/1\/15\/58599912\/ciae087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T18:12:42Z","timestamp":1721412762000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/79\/1\/15\/7612213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,21]]},"published-print":{"date-parts":[[2024,7,19]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae087","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7,15]]},"published":{"date-parts":[[2024,2,21]]}}}